The role of BAFF and APRIL in IgA nephropathy: pathogenic mechanisms and targeted therapies
Frontiers in Nephrology · 01.02.2024 · 3
DOI: 10.3389/fneph.2023.1346769 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Nephrology, online erschienen am 01.02.2024. Verfasst von Chee Kay Cheung und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiovascular Sciences, University of Leicester, Leicester, United Kingdom. Die Arbeit wurde bisher 97-mal zitiert (Crossref) und nennt 114 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Immunoglobulin A nephropathy (IgAN), characterized by mesangial deposition of galactose-deficient-IgA1 (Gd-IgA1), is the most common biopsy-proven primary glomerulonephritis worldwide. Recently, an improved understanding of its underlying pathogenesis and the substantial risk of progression to kidney failure has emerged. The “four-hit hypothesis” of IgAN pathogenesis outlines a process that begins with elevated circulating levels of Gd-IgA1 that trigger autoantibody production. This results in the formation and deposition of immune complexes in the mesangium, leading to inflammation and kidney injury. Key mediators of the production of Gd-IgA1 and its corresponding autoantibodies are B-cell activating factor (BAFF), and A proliferation-inducing ligand (APRIL), each playing essential roles in the survival and maintenance of B cells and humoral immunity. Elevated serum levels of both BAFF and APRIL are observed in patients with IgAN and correlate with disease severity. This review explores the complex pathogenesis of IgAN, highlighting the pivotal roles of BAFF and APRIL in the interplay between mucosal hyper-responsiveness, B-cell activation, and the consequent overproduction of Gd-IgA1 and its autoantibodies that are key features in this disease. Finally, the potential therapeutic benefits of inhibiting BAFF and APRIL in IgAN, and a summary of recent clinical trial data, will be discussed.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Cardiovascular Sciences, University of Leicester, Leicester, United Kingdom.
- John Walls Renal Unit, University Hospitals of Leicester National Health Service (NHS) Trust, Leicester, United Kingdom.
- The Kidney & Transplant Practice, Mount Elizabeth Novena Hospital, Singapore.
- Renal Division in the Department of Medicine, Peking University First Hospital, Beijing, China.
- Department of Nephrology, First School of Medicine and General University Hospital, Charles University, Prague, Czechia.
- Department of Medicine, Stanford University, Stanford, CA, United States.
Zitieren
APA
Cheung, C. K., Barratt, J., Liew, A., Zhang, H., Tesar, V., & Lafayette, R. (2024). The role of BAFF and APRIL in IgA nephropathy: pathogenic mechanisms and targeted therapies. Frontiers in Nephrology, 3. https://doi.org/10.3389/fneph.2023.1346769
Vancouver
Cheung CK, Barratt J, Liew A, Zhang H, Tesar V, Lafayette R. The role of BAFF and APRIL in IgA nephropathy: pathogenic mechanisms and targeted therapies. Frontiers in Nephrology. 2024;3. doi:10.3389/fneph.2023.1346769
BibTeX
@article{Cheung2024,
author = {Cheung, Chee Kay and Barratt, Jonathan and Liew, Adrian and Zhang, Hong and Tesar, Vladimir and Lafayette, Richard},
title = {The role of BAFF and APRIL in IgA nephropathy: pathogenic mechanisms and targeted therapies},
journal = {Frontiers in Nephrology},
year = {2024},
volume = {3},
doi = {10.3389/fneph.2023.1346769}
}
EUVIMED